IL-6 is another key regulator of the cytokine network in ovarian cancer cells and treatment of ovarian cancer patients with an anti-IL6 therapeutic antibody has also been shown to have some clinical activity, with periods of disease stabilization in some patients, reduced systemic cytokine and c-reactive protein levels. Here, IL6 is linked to ovarian carcinoma.